U.S. flag

An official website of the United States government

Format

Send to:

Choose Destination

Gastric neuroendocrine tumor G2

MedGen UID:
474040
•Concept ID:
C3272407
•
Neoplastic Process
Synonyms: Gastric NET G2; gastric NET G2; Gastric Neuroendocrine Tumor G2; gastric neuroendocrine tumor G2
 
Monarch Initiative: MONDO:0024642

Definition

A well differentiated, intermediate grade neoplasm with neuroendocrine differentiation that arises from the stomach. The mitotic count is 2-20 per 10 HPF and/or the Ki67 index is 3 to 20 percent. [from NCI]

Term Hierarchy

CClinical test,  RResearch test,  OOMIM,  GGeneReviews,  VClinVar  
  • CROGVGastric neuroendocrine tumor G2

Professional guidelines

PubMed

Systemic Therapy for Tumor Control in Metastatic Well-Differentiated Gastroenteropancreatic Neuroendocrine Tumors: ASCO Guideline.
Del Rivero J, Perez K, Kennedy EB, Mittra ES, Vijayvergia N, Arshad J, Basu S, Chauhan A, Dasari AN, Bellizzi AM, Gangi A, Grady E, Howe JR, Ivanidze J, Lewis M, Mailman J, Raj N, Soares HP, Soulen MC, White SB, Chan JA, Kunz PL, Singh S, Halfdanarson TR, Strosberg JR, Bergsland EK
J Clin Oncol 2023 Nov 10;41(32):5049-5067. Epub 2023 Sep 29 doi: 10.1200/JCO.23.01529. PMID: 37774329
Gastroenteropancreatic Well-Differentiated Grade 3 Neuroendocrine Tumors: Review and Position Statement.
Coriat R, Walter T, Terris B, Couvelard A, Ruszniewski P
Oncologist 2016 Oct;21(10):1191-1199. Epub 2016 Jul 8 doi: 10.1634/theoncologist.2015-0476. PMID: 27401895Free PMC Article
Medical treatment of gastrinomas.
Auernhammer CJ, Göke B
Wien Klin Wochenschr 2007;119(19-20):609-15. doi: 10.1007/s00508-007-0877-1. PMID: 17985097

Recent clinical studies

Etiology

Therapeutic Challenges for Gastric Neuroendocrine Neoplasms: Take It or Leave It?
Cavalcoli F, Gallo C, Coltro LA, Rausa E, Cantù P, Invernizzi P, Massironi S
Medicina (Kaunas) 2023 Oct 1;59(10) doi: 10.3390/medicina59101757. PMID: 37893475Free PMC Article
Intratumoral dendritic cells and T cells predict survival in gastroenteropancreatic neuroendocrine neoplasms.
Werner W, Detjen K, Bruneau A, Lurje I, Nestel N, Jann H, Tacke F, Wiedenmann B, Roderburg C, Hammerich L
Endocr Relat Cancer 2023 Jul 1;30(7) Epub 2023 Jun 2 doi: 10.1530/ERC-22-0357. PMID: 37130269
Gastric neuroendocrine neoplasms and precursor lesions: Case reports and literature review.
Boeriu A, Dobru D, Fofiu C, Brusnic O, Onişor D, Mocan S
Medicine (Baltimore) 2022 Jan 14;101(2):e28550. doi: 10.1097/MD.0000000000028550. PMID: 35029217Free PMC Article
Vitamin D deficiency and tumor aggressiveness in gastroenteropancreatic neuroendocrine tumors.
Altieri B, Barrea L, Modica R, Bottiglieri F, de Cicco F, Muscogiuri G, Circelli L, Savarese G, Di Somma C, Savastano S, Colao A, Faggiano A
Endocrine 2022 Feb;75(2):623-634. Epub 2021 Sep 17 doi: 10.1007/s12020-021-02869-w. PMID: 34533768
Gastric neuroendocrine neoplasms and related precursor lesions.
La Rosa S, Vanoli A
J Clin Pathol 2014 Nov;67(11):938-48. Epub 2014 Jul 22 doi: 10.1136/jclinpath-2014-202515. PMID: 25053544

Diagnosis

HepPar1 and GATA-3 Expression in Neuroendocrine Neoplasms: A Potential Trap for Pathologic Diagnosis.
Xu L, Yu G, Jiang L, Song X, Qu G, Luo J, Cai L
Appl Immunohistochem Mol Morphol 2023 Nov-Dec 01;31(10):668-672. Epub 2023 Sep 26 doi: 10.1097/PAI.0000000000001160. PMID: 37751245
Gastric neuroendocrine neoplasms and precursor lesions: Case reports and literature review.
Boeriu A, Dobru D, Fofiu C, Brusnic O, Onişor D, Mocan S
Medicine (Baltimore) 2022 Jan 14;101(2):e28550. doi: 10.1097/MD.0000000000028550. PMID: 35029217Free PMC Article
Recurrence and metastatic potential in Type 1 gastric neuroendocrine neoplasms.
Daskalakis K, Tsoli M, Karapanagioti A, Chrysochoou M, Thomas D, Sougioultzis S, Karoumpalis I, Kaltsas GA, Alexandraki KI
Clin Endocrinol (Oxf) 2019 Oct;91(4):534-543. Epub 2019 Jul 7 doi: 10.1111/cen.14055. PMID: 31254407
Clinicopathological features and outcome of type 3 gastric neuroendocrine tumours.
Min BH, Hong M, Lee JH, Rhee PL, Sohn TS, Kim S, Kim KM, Kim JJ
Br J Surg 2018 Oct;105(11):1480-1486. Epub 2018 Jun 12 doi: 10.1002/bjs.10901. PMID: 29893418
Gastric neuroendocrine neoplasms and related precursor lesions.
La Rosa S, Vanoli A
J Clin Pathol 2014 Nov;67(11):938-48. Epub 2014 Jul 22 doi: 10.1136/jclinpath-2014-202515. PMID: 25053544

Therapy

Systemic Therapy for Tumor Control in Metastatic Well-Differentiated Gastroenteropancreatic Neuroendocrine Tumors: ASCO Guideline.
Del Rivero J, Perez K, Kennedy EB, Mittra ES, Vijayvergia N, Arshad J, Basu S, Chauhan A, Dasari AN, Bellizzi AM, Gangi A, Grady E, Howe JR, Ivanidze J, Lewis M, Mailman J, Raj N, Soares HP, Soulen MC, White SB, Chan JA, Kunz PL, Singh S, Halfdanarson TR, Strosberg JR, Bergsland EK
J Clin Oncol 2023 Nov 10;41(32):5049-5067. Epub 2023 Sep 29 doi: 10.1200/JCO.23.01529. PMID: 37774329
Heterogeneity of grade 3 gastroenteropancreatic neuroendocrine carcinomas: New insights and treatment implications.
Fazio N, Milione M
Cancer Treat Rev 2016 Nov;50:61-67. Epub 2016 Aug 28 doi: 10.1016/j.ctrv.2016.08.006. PMID: 27636009
Clinicopathological features and prognosis of gastroenteropancreatic neuroendocrine tumors: analysis from a single-institution.
Zeng YJ, Liu L, Wu H, Lai W, Cao JZ, Xu HY, Wang J, Chu ZH
Asian Pac J Cancer Prev 2013;14(10):5775-81. doi: 10.7314/apjcp.2013.14.10.5775. PMID: 24289577
Biotherapies for GEP-NETs.
Öberg K
Best Pract Res Clin Gastroenterol 2012 Dec;26(6):833-41. doi: 10.1016/j.bpg.2013.01.001. PMID: 23582922
Medical treatment of gastrinomas.
Auernhammer CJ, Göke B
Wien Klin Wochenschr 2007;119(19-20):609-15. doi: 10.1007/s00508-007-0877-1. PMID: 17985097

Prognosis

Therapeutic Challenges for Gastric Neuroendocrine Neoplasms: Take It or Leave It?
Cavalcoli F, Gallo C, Coltro LA, Rausa E, Cantù P, Invernizzi P, Massironi S
Medicina (Kaunas) 2023 Oct 1;59(10) doi: 10.3390/medicina59101757. PMID: 37893475Free PMC Article
Intratumoral dendritic cells and T cells predict survival in gastroenteropancreatic neuroendocrine neoplasms.
Werner W, Detjen K, Bruneau A, Lurje I, Nestel N, Jann H, Tacke F, Wiedenmann B, Roderburg C, Hammerich L
Endocr Relat Cancer 2023 Jul 1;30(7) Epub 2023 Jun 2 doi: 10.1530/ERC-22-0357. PMID: 37130269
Vitamin D deficiency and tumor aggressiveness in gastroenteropancreatic neuroendocrine tumors.
Altieri B, Barrea L, Modica R, Bottiglieri F, de Cicco F, Muscogiuri G, Circelli L, Savarese G, Di Somma C, Savastano S, Colao A, Faggiano A
Endocrine 2022 Feb;75(2):623-634. Epub 2021 Sep 17 doi: 10.1007/s12020-021-02869-w. PMID: 34533768
Chemotherapy in NEN: still has a role?
Espinosa-Olarte P, La Salvia A, Riesco-Martinez MC, Anton-Pascual B, Garcia-Carbonero R
Rev Endocr Metab Disord 2021 Sep;22(3):595-614. Epub 2021 Apr 11 doi: 10.1007/s11154-021-09638-0. PMID: 33843007Free PMC Article
Gastric neuroendocrine neoplasms and related precursor lesions.
La Rosa S, Vanoli A
J Clin Pathol 2014 Nov;67(11):938-48. Epub 2014 Jul 22 doi: 10.1136/jclinpath-2014-202515. PMID: 25053544

Clinical prediction guides

Therapeutic Challenges for Gastric Neuroendocrine Neoplasms: Take It or Leave It?
Cavalcoli F, Gallo C, Coltro LA, Rausa E, Cantù P, Invernizzi P, Massironi S
Medicina (Kaunas) 2023 Oct 1;59(10) doi: 10.3390/medicina59101757. PMID: 37893475Free PMC Article
Systemic Therapy for Tumor Control in Metastatic Well-Differentiated Gastroenteropancreatic Neuroendocrine Tumors: ASCO Guideline.
Del Rivero J, Perez K, Kennedy EB, Mittra ES, Vijayvergia N, Arshad J, Basu S, Chauhan A, Dasari AN, Bellizzi AM, Gangi A, Grady E, Howe JR, Ivanidze J, Lewis M, Mailman J, Raj N, Soares HP, Soulen MC, White SB, Chan JA, Kunz PL, Singh S, Halfdanarson TR, Strosberg JR, Bergsland EK
J Clin Oncol 2023 Nov 10;41(32):5049-5067. Epub 2023 Sep 29 doi: 10.1200/JCO.23.01529. PMID: 37774329
Intratumoral dendritic cells and T cells predict survival in gastroenteropancreatic neuroendocrine neoplasms.
Werner W, Detjen K, Bruneau A, Lurje I, Nestel N, Jann H, Tacke F, Wiedenmann B, Roderburg C, Hammerich L
Endocr Relat Cancer 2023 Jul 1;30(7) Epub 2023 Jun 2 doi: 10.1530/ERC-22-0357. PMID: 37130269
Recurrence and metastatic potential in Type 1 gastric neuroendocrine neoplasms.
Daskalakis K, Tsoli M, Karapanagioti A, Chrysochoou M, Thomas D, Sougioultzis S, Karoumpalis I, Kaltsas GA, Alexandraki KI
Clin Endocrinol (Oxf) 2019 Oct;91(4):534-543. Epub 2019 Jul 7 doi: 10.1111/cen.14055. PMID: 31254407
Microenvironment and tumor inflammatory features improve prognostic prediction in gastro-entero-pancreatic neuroendocrine neoplasms.
Milione M, Miceli R, Barretta F, Pellegrinelli A, Spaggiari P, Tagliabue G, Centonze G, Paolino C, Mangogna A, Kankava K, Pusceddu S, Giacomelli L, Corti A, Cotsoglou C, Mazzaferro V, Sozzi G, de Braud F, Pruneri G, Anichini A
J Pathol Clin Res 2019 Oct;5(4):217-226. Epub 2019 Jul 9 doi: 10.1002/cjp2.135. PMID: 31136102Free PMC Article

Supplemental Content

Table of contents

    Clinical resources

    Practice guidelines

    • PubMed
      See practice and clinical guidelines in PubMed. The search results may include broader topics and may not capture all published guidelines. See the FAQ for details.
    • Bookshelf
      See practice and clinical guidelines in NCBI Bookshelf. The search results may include broader topics and may not capture all published guidelines. See the FAQ for details.

    Consumer resources

    Reviews

    Related information

    • PMC Articles
      Related information in PubMed Central Links
    • PubMed
      Related literature resources in PubMed

    Recent activity

    Clear Turn Off Turn On

    Your browsing activity is empty.

    Activity recording is turned off.

    Turn recording back on

    See more...